Sugi Predict

Sugi Predict / Compounds / SCHEMBL390884

SCHEMBL390884

SCHEMBL390884

CC(C)(C)OC(=O)NC1(C(=O)O)CCN(c2ncnc3[nH]ccc23)CC1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 7/20 0.58
▸ AKT2 P31751 5/20 0.52
▸ ROCK2 O75116 3/20 0.51
▸ AKT1 P31749 3/20 0.51
▸ AKT3 Q9Y243 1/20 0.51
▸ PRKACA P17612 1/20 0.49
▸ PRKACG P22612 1/20 0.49
▸ PRKACB P22694 1/20 0.49
▸ LIMK1 P53667 1/20 0.49
▸ LIMK2 P53671 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ ENPP1 P22413 1/20 0.49
▸ KIT P10721 1/20 0.49
▸ LCK P06239 1/20 0.47
▸ HTR2C P28335 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31374403 1.00 JAK3 (0.58) JAK3AKT2ROCK2AKT1AKT3
SCHEMBL2780762 0.88 JAK3 (0.54) JAK3AKT2ROCK2AKT1AKT3
SCHEMBL29036015 0.84 AKT1 (0.58) JAK3AKT2ROCK2AKT1AKT3
SCHEMBL29036005 0.84 AKT1 (0.58) JAK3AKT2ROCK2AKT1AKT3
SCHEMBL28781689 0.84 JAK3 (0.59) JAK3AKT2ROCK2AKT1AKT3
SCHEMBL3491986 0.84 PDGFRB (0.47) AKT2ROCK2AKT1PRKACAPRKACG
SCHEMBL10156821 0.84 JAK3 (0.59) JAK3AKT2ROCK2AKT1AKT3
SCHEMBL29157947 0.84 AKT1 (0.57) JAK3AKT2ROCK2AKT1AKT3
SCHEMBL30012817 0.84 AKT1 (0.57) JAK3AKT2ROCK2AKT1AKT3
SCHEMBL29157946 0.84 AKT1 (0.57) JAK3AKT2ROCK2AKT1AKT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119684280-A Targeting protein arginine methylation proximity-induced small molecule chimeric platform MeTAG and application thereof 西安交通大学医学院第一附属医院 2025-03-25 — — CN disclosed
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
CN-115232130-B APN and AKT double-target inhibitor and preparation method and application thereof 山东大学 2024-01-12 — — CN disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20230167106-A1 SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE ICAHN SCHOOL MED MOUNT SINAI (US) 2023-06-01 — — US disclosed
US-20230167106-A1 SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE ICAHN SCHOOL MED MOUNT SINAI (US) 2023-06-01 — — US disclosed
CN-115232130-A APN and AKT double-target-point inhibitor and preparation method and application thereof 山东大学 2022-10-25 — — CN disclosed
US-11472799-B2 Serine threonine kinase (AKT) degradation / disruption compounds and methods of use ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-10-18 — — US disclosed
EP-2125805-A1 SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY Astex Therapeutics Limited (GB) 2009-12-02 — — EP disclosed
CN-101490050-A Pharmaceutical compounds ASTEX THERAPEUTICS LTD (GB) 2009-07-22 — — CN disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed
WO-2008075109-A1 SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2008-06-26 — — WO disclosed
WO-2008075109-A1 SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2008-06-26 — — WO disclosed
WO-2008075110-A1 SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY ASTEX THERAPEUTICS LIMITED (GB) 2008-06-26 — — WO disclosed
WO-2008075110-A1 SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY ASTEX THERAPEUTICS LIMITED (GB) 2008-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 JAK3 210/4885AKT2 4/4885ROCK2 60/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 JAK3 210/4885AKT2 4/4885ROCK2 60/4885
US-20230167106-A1 SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE MKNK1, MKNK2, MTOR JAK3 1196/4885AKT2 6/4885ROCK2 2409/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 JAK3 249/4885AKT2 6/4885ROCK2 85/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 JAK3 210/4885AKT2 4/4885ROCK2 60/4885
US-11472799-B2 Serine threonine kinase (AKT) degradation / disruption compounds and methods of use MKNK1, MKNK2, MTOR JAK3 1196/4885AKT2 6/4885ROCK2 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.